The maintenance of a Buy rating and a $6 price target by a reputable analyst firm like HC Wainwright & Co. is a positive signal for Cidara Therapeutics. It suggests confidence in the company's future performance and potential for growth, which could positively influence investor sentiment and potentially lead to an increase in stock price in the short term.